您现在位置:健康网-医药产业 >> 研究报告 >> English reports >> English reports >> 浏览医药行业研究报告
健康网讯:
Research Report on Chinese Bulk Cephalosporin Industry Publisher: Orient Health Electronic Commercial(Beijing)co.,Ltd Published: July 2006 Format: Hardcopy and Adobe PDF Price: US$6,700 Contact: Mr. Bian chenghua Ms. Wu huifang Tel.: 86-10-68012929-2116/2101 Fax: 86-10-68012929-2008 E-mail: bianch@healthoo.com wuhf@healthoo.com http://www.healthoo.com Directory 1、Industry scale of China's chemical API 1.1 Basic situation and product structure of chemical API 1.2 Developing trend of chemical API lately years 1.3 Output structure of 24 Categories of chemical API last year 1.4 Output and production value of chemical API in differnet provinces 1.5 Output and share of antibiotic bulk drugs 2 Overview of antibiotic bulk drugs 2.1 Categories 2.2 Therapeutic mechanisms 2.3 Cephalosporin nucleus series 2.4 Product structure 3 7-ACA series 3.1 About 7-ACA 3.1.1 Output,production capacity,status of import and export,key enterprises 3.1.2 Price trend 3.1.3 Trend of import and export 3.1.4 Connections of 7-ACA with lower-stream product 3.1.5 Market forecast 3.2 Analysis about Cefazolin 3.2.1 Output,production capacity,status of import and export,key enterprises 3.2.2 Price trend 3.2.3 Market forecast 3.2.4 Connections of Cefazolin with lower-stream product 3.3 Analysis about Ceftriaxone 3.3.1 Output,production capacity,status of import and export,key enterprises 3.3.2 Price trend 3.3.3 Connections of Ceftriaxone with lower-stream product 3.3.4 Market forecast 3.3.5 Export trend 3.4 Analysis about Cefoperazone 3.4.1 Output,production capacity,status of import and export,key enterprises 3.4.2 Price trend 3.4.3 Status of production and sales and Market forecast 3.4.4 Connections of Cefoperazone with lower-stream product 3.4.5 Export trend 3.5 Analysis about Cefotaxime 3.5.1 Output,production capacity,key enterprises 3.5.2 Price trend 3.5.3 Export status 3.5.4 Status of production and sales and Market forecast 3.5.5 Connections of Cefotaxime with lower-stream product 3.6 Analysis about Ceftazidime 3.6.1 Output,production capacity,status of import and export,key enterprises 3.6.2 Price trend 3.6.3 Connections of Ceftazidime with lower-stream product 3.6.4 Status of production and sales and Market forecast 3.7 Analysis about Ceftazidime 3.7.1 Output,production capacity,key enterprises 3.7.2 Price trend and import & export 3.7.3 Status of production and sales and Market forecast 4 7-ADCA series 4.1 Output,production capacity,enterprise's share 4.1.1 Output,production capacity,status of import and export,key enterprises 4.1.2 Price trend 4.1.3 Connections of 7-ADCA with lower-stream product 4.1.4 Status of production and sales and Market forecast 4.2 Cefalexin 4.2.1 Output,production capacity,status of import and export,key enterprises 4.1.2 Price trend 4.2.3 Connections of Cefalexin with lower-stream product 4.2.4 Connections of Cefalexin with lower-stream product 4.3 Cefradine 4.3.1 Output,production capacity,status of import and export,key enterprises 4.3.2 Price trend 4.3.3 Status of production and sales and Market forecast 4.3.4 Connections of Cefradine with lower-stream product 4.4 Cefadroxil 4.4.1 Output,production capacity,status of import and export,key enterprises 4.4.2 Price trend 4.4.3 Status of production and sales and Market forecast 4.4.4 Connections of Cefradine with lower-stream product 4.5 Other antibiotic bulk drugs 5 About key enterprise 5.1 Shijiazhuang Pharmaceutical Group Co.,Ltd 5.2 Shandong Lukang Pharmaceutical Group Co.,Ltd 5.3 Fujian antibiotic Pharmaceutical Co.,Ltd 5.4 Suzhou Dongrui Pharmaceutical Co.,Ltd 5.5 Zhuhai Federal Pharmaceutical Company, Ltd 5.6 Shandong xinhua-chemfermPharmaceutical Co., Ltd 5.7 North China pharmaceutical Group Corporation 5.8 Harbin General Pharmaceutical Factory 5.9 Zhejiang Yongning Pharmaceutical Factory 5.10 Guangzhou Baiyunshan Pharmaceutical Co., Ltd
|